Prolyl oligopeptidase regulates dopamine transporter oligomerization and phosphorylation in a PKC and ERK independent manner

Supplementary Material

Ulrika H. Julku¹, Maria Jäntti¹, Reinis Svarcbahs¹, Timo T. Myöhänen^{1,2}

Address:	¹ Division of Pharmacology and Pharmacotherapy / Drug Research Program
	Faculty of Pharmacy
	University of Helsinki
	Viikinkaari 5E (PO Box 56)
	00014 University of Helsinki
	FINLAND
	² Integrative Physiology and Pharmacology Unit / Institute of Biomedicine
	Faculty of Medicine
	University of Turku
	Kiinanmyllyntie 10
	FI-20014 University of Turku
	FINLAND

Tel: +358 50 4480769

E-mail: timo.myohanen@helsinki.fi




Figure S1. Characterization of DAT (MAB369, Merck Millipore) and pDAT (ab183486, Abcam) antibodies by Western blotting. HEK-293 cells were transfected with mock or DAT plasmid, and also non-transfected cells were used as control. GAPDH was used as a loading control, because expression of β -actin was not similar in transfected and non-transfected cells (data not shown). DAT antibody showed specific binding on DAT transfected cells, but only oligomeric DAT was detected due to high molecular weight band on Western blotting. pDAT antibody had also unspecific binding on Western blotting, but PKC activation induced increase (Fig. 3) confirmed that antibody binds also to pDAT. Unspecific binding of pDAT antibody might prevent detection of small changes in pDAT expression, but massive increase in pDAT expression is still detectable with this antibody.

Figure 1C	
250 kDa 150 kDa 100 kDa Figure 1C oDAT	250 kDa 150 kDa 100 kDa 75 kDa
	Figure 1C pDAT
50 kDa 37 kDa	50 kDa
Figure 1C ERK	
	Figure 1C pERK
50 kDa	50 kDa
Figure 1C b-actin	Figure 1C b-actin

Figure 2G		
250 kDa 150 kDa 100 kDa 75 kDa	250 kDa 150 kDa 100 kDa 75 kDa Figure 2G pDAT	
Figure 2G oDAT	50 kDa	
50 kDa	37 kDa	
37 kDa		
	Figure 2G pERK	
Figure 2G ERK	50 kDa	
50 kDa 🛖 🛖 🛥 🛥 🛶 🛶	37 kDa	
Figure 2G b-actin	Figure 2G b-actin	

Figure S2. Raw Western blot images for figures 1C and 2G.

Figure 2H		
250 kDa 150 kDa 100 kDa Figure 2H oDAT	250 kDa 150 kDa 100 kDa 75 kDa Figure 2H pDAT	
50 kDa	50 kDa	
37 kDa	37 kDa	
Figure 2H ERK	Figure 2H pERK	
^{50 kDa}	50 kDa 37 kDa	
Figure 2H b-actin	Figure 2H b-actin	

Figure 3G		
250 kDa 150 kDa 400 kDa 75 kDa	250 kDa 150 kDa 100 kD 75 kD	
Figure 3G oDAT	Figure 3G pDAT	
50 kDa 37 kDa	50 kDa 37 kDa	
Figure 3G ERK	Figure 3G pERK	
50 600a 37 600a	50 kD 37 kD	
Figure 3G b-actin	Figure 3G b-actin	

Figure S3. Raw Western blot images for figures 2H and 3G.




Figure S4. ERK, and pERK were measured by Western blotting in wild-type HEK-293 and stable PREPko cells transfected with DAT and mock, DAT and PREP, or DAT and inactive PREP (S554A-PREP) (A-B), or DAT and mock, DAT and aSyn or DAT, aSyn and PREP (C-D). DAT and mock, DAT and aSyn, and DAT, aSyn and PREP transfected wild-type HEK-

293cells were treated with PREP inhibitor KYP-2047 or vehicle (E-F). Optical density values were normalized to the loading control (β -actin) optical density. Bars represent mean \pm SEM, n = 6




Figure S5. ERK, and pERK were measured by Western blotting in wild-type HEK-293 cells transfected with DAT. Cells were starved in serum-free media for 2 hours before 30 minutes treatment with 1 μ M KYP, 1 μ M PMA or 1 μ M KYP + 1 μ M PMA or treated for 30 minutes with 1 μ M KYP, 1 μ M Gö-9683 or 1 μ M KYP + 1 μ M Gö-6983 without prior starving. Optical density values were normalized to the loading control (β -actin) optical density. KYP or PMA did not have an effect on ERK A) but PMA and combination of KYP and PMA increased pERK (B). KYP or Gö-6983 did not have an effect on ERK (C) but Gö-6983 and combination of KYP and Gö-6938 decreased phosphorylated ERK (D). Bars represent mean \pm SEM, n = 6, ****p < 0.0001, one-way ANOVA, Tukey's post-hoc test.